This pathway is frequently altered in various cancers, and PI3K inhibitors, including the selective PI3K inhibitor alpelisib, which has been approved by the FDA for the treatment of PIK3CA-mutant HR-positive, HER2-negative breast cancer (based on the SOLAR-1 trial), have been developed [92]. The gene discussed is ERBB2; the disease is breast cancer.